Unavailable
Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $NTRA
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/13/2025 | $251.00 | Outperform | RBC Capital Mkts |
1/23/2025 | $200.00 | Overweight | Barclays |
6/3/2024 | $142.00 | Buy | Jefferies |
4/8/2024 | $117.00 | Buy | Craig Hallum |
2/20/2024 | $68.00 → $85.00 | Strong Buy → Outperform | Raymond James |
12/29/2023 | $75.00 → $85.00 | Buy | BTIG Research |
12/14/2023 | $70.00 | Buy | Guggenheim |
12/13/2023 | $70.00 | Outperform | Wolfe Research |
DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting
First-of-its-kind prospective trial evaluates the association between dd-cfDNA and clinical outcomes in heart transplantation using Prospera™ Heart with Donor Quantity Score (DQS) Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, announced that it will share results from the DEFINE-HT study in a late-breaking oral presentation at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting on April 29, 2025. DEFINE-HT is the first prospective, multicenter study in heart transplant recipients designed to assess whether elevated levels of donor-derived cell-free DNA (dd-cfDNA), as measured by Prospera Heart with DQS, are associated
Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer
HEROES is Natera's first clinical trial using Signatera™ to guide de-escalation of therapy in patients with metastatic HER2+ breast cancer Approximately 170 patients are expected to enroll in up to 35 sites in France Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the HEROES clinical trial. HEROES is a multi-center, phase II trial that explores the discontinuation or de-escalation of anti-HER2 targeted therapy among patients with metastatic HER2+ breast cancer. The trial is supported by funding from the French Ministry of Health through the Hospital Clinical Research Program (PHRC) and is being spons
Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today announced that the U.S. Patent and Trademark Office has issued Natera a new patent related to testing of single nucleotide variants in circulating-tumor DNA (ctDNA). This builds on Natera's extensive intellectual property estate, including a strong portfolio of molecular residual disease testing (MRD) patents for whole exome and whole genome sequencing. U.S. patent No. 12,203,142 relates to certain methods of preparation useful for tumor-informed ctDNA monitoring using whole exome or whole genome sequencing. The patent describes various modes of target enrichment in the plasma, including both multiplex
RBC Capital Mkts initiated coverage on Natera with a new price target
RBC Capital Mkts initiated coverage of Natera with a rating of Outperform and set a new price target of $251.00
Barclays initiated coverage on Natera with a new price target
Barclays initiated coverage of Natera with a rating of Overweight and set a new price target of $200.00
Jefferies resumed coverage on Natera with a new price target
Jefferies resumed coverage of Natera with a rating of Buy and set a new price target of $142.00
CEO AND PRESIDENT Chapman Steven Leonard sold $978,678 worth of shares (6,702 units at $146.03), decreasing direct ownership by 3% to 203,354 units (SEC Form 4)
4 - Natera, Inc. (0001604821) (Issuer)
CHIEF FINANCIAL OFFICER Brophy Michael Burkes sold $115,661 worth of shares (792 units at $146.04), decreasing direct ownership by 1% to 71,869 units (SEC Form 4)
4 - Natera, Inc. (0001604821) (Issuer)
CO-FOUNDER Sheena Jonathan sold $856,410 worth of shares (5,881 units at $145.62), decreasing direct ownership by 1% to 258,319 units (SEC Form 4)
4 - Natera, Inc. (0001604821) (Issuer)
Natera Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
8-K - Natera, Inc. (0001604821) (Filer)
SEC Form 144 filed by Natera Inc.
144 - Natera, Inc. (0001604821) (Subject)
SEC Form S-8 filed by Natera Inc.
S-8 - Natera, Inc. (0001604821) (Filer)
Experienced Biotech Executive and Deal Maker Joins Zephyr AI as Chief Business Officer
Zephyr AI, Inc. ("Zephyr AI"), a company building novel transparent AI to address unmet needs across the full spectrum of precision medicine – from prevention to treatment – to improve patients' lives, today announced the appointment of Eric Lindquist as its new Chief Business Officer. "At Zephyr AI, we have set out to use artificial intelligence and machine learning to bring precision medicine to those suffering from cancer, and our goal is for patients everywhere to be able to find the right treatment, delivered by the right provider, when they need it, enabling them to live healthier and fuller lives," said Grant Verstandig, Co-Founder and Executive Chairman of Zephyr AI. "Eric has bee
Natera Appoints Ruth E. Williams-Brinkley to its Board of Directors
Seasoned healthcare executive with extensive leadership experience in health plans, hospital operations, and physician relations Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced that Ruth E. Williams-Brinkley has been appointed to the Company's board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230223005436/en/(Photo: Business Wire) Williams-Brinkley has three decades of healthcare industry experience. She currently serves as president of Kaiser Permanente Health Plan of the Mid-Atlantic States (KPMAS), where she oversees the company's care delivery and health plan operations
Natera Appoints Minetta Liu, M.D. as Chief Medical Officer of Oncology
AUSTIN, Texas, May 24, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced the appointment of Minetta Liu, M.D., as its new chief medical officer (CMO) of oncology. In this role, Dr. Liu will set the direction for the company's clinical and scientific roadmap in oncology, primarily to prove the clinical utility of Signatera™ and incorporate it into standard medical practice across tumor types. "I am very pleased to welcome Dr. Liu to Natera," said Solomon Moshkevich, general manager of oncology at Natera. "As a highly reg
Natera Reports Fourth Quarter and Full Year 2024 Financial Results
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the fourth quarter and full year ended December 31, 2024. Recent Financial Highlights Generated total revenues of $476.1 million in the fourth quarter of 2024, compared to $311.1 million in the fourth quarter of 2023, an increase of 53.0%. Product revenues grew 53.9% over the same period. Generated a gross margin of 62.9% in the fourth quarter of 2024, compared to a gross margin of 51.4% in the fourth quarter of 2023. Generated total revenues of $1,696.9 million in the full year of 2024, compared to $1,082.6 million in the full year 2023, an increase of 56.7%
Natera to Report its Fourth Quarter and Full Year Results on February 27, 2025
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2024, after the market closes on Feb. 27, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information Event: Natera's Fourth Quarter & Full Year 2024 Financial Results Date: February 27, 2025 Time: 1:30 p.m. PT (4:30 p.m. ET) Live Dial-In: 1-888-770-7321 (Domestic) 1-929-201-7101 (International) Conference ID: 7684785 Webcast: https://events.q4inc.com/attendee/538630796 A webca
Natera Reports Third Quarter 2024 Financial Results
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the third quarter ended September 30, 2024. Recent Strategic and Financial Highlights Generated total revenues of $439.8 million in the third quarter of 2024, compared to $268.3 million in the third quarter of 2023, a record increase of 63.9%. Product revenues grew 64.4% over the same period. Generated a gross margin of 61.8% in the third quarter of 2024, compared to a gross margin of 45.1% in the third quarter of 2023. Processed approximately 775,800 tests in the third quarter of 2024, compared to approximately 626,000 tests in the third quarter of 2023, an
Amendment: SEC Form SC 13G/A filed by Natera Inc.
SC 13G/A - Natera, Inc. (0001604821) (Subject)
SEC Form SC 13G/A filed by Natera Inc. (Amendment)
SC 13G/A - Natera, Inc. (0001604821) (Subject)
SEC Form SC 13G/A filed by Natera Inc. (Amendment)
SC 13G/A - Natera, Inc. (0001604821) (Subject)